(XLV) Health Care Sector Fund - Overview
ETF Category: Health | Exchange: NYSE ARCA (USA) | Market Cap: 38.674m USD | Total Return: 3.6% in 12m
Etf
Pharmaceuticals, Equipment, Providers, Biotechnology, Technology
Total Rating 37
Risk 66
Buy Signal -0.17
Risk 5d forecast
Volatility16.1%
Rel. Tail Risk-2.47%
Reward TTM
Sharpe Ratio-0.03
Alpha-6.79
Character TTM
Beta0.410
Beta Downside0.443
Drawdowns 3y
Max DD17.11%
CAGR/Max DD0.33
Description: XLV Health Care Sector Fund
XLV is an exchange-traded fund (ETF) tracking a healthcare sector index. It primarily invests in the securities of that index, holding at least 95% of its assets in those components.
The funds holdings span diverse healthcare industries. These include pharmaceuticals, a sector focused on drug discovery and manufacturing, and biotechnology, which utilizes biological processes for product development. Other industries within the fund are healthcare equipment and supplies, healthcare providers and services, life sciences tools and services, and health care technology.
XLV is classified as non-diversified. Further research on ValueRay can provide more in-depth analysis of its holdings and performance.
- Pharmaceutical patent expirations impact drug manufacturer revenue
- Healthcare policy changes create regulatory uncertainty
- Medical device innovation drives sector growth
- Biotechnology breakthroughs boost investment sentiment
- Healthcare service demand increases with aging population
What is the price of XLV shares?
As of April 03, 2026, the stock is trading at USD 146.61 with a total of 17,728,312 shares traded.
Over the past week, the price has changed by +0.73%, over one month by -7.01%, over three months by -5.21% and over the past year by +3.55%.
Over the past week, the price has changed by +0.73%, over one month by -7.01%, over three months by -5.21% and over the past year by +3.55%.
Is XLV a buy, sell or hold?
Health Care Sector Fund has no consensus analysts rating.
What are the forecasts/targets for the XLV price?
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
External Resources